Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8835488 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(9 years from now) | |
US9309234 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(9 years from now) | |
US11077098 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9642842 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Oct 30, 2025 |
NCE-1 date: October, 2024
Market Authorisation Date: 30 October, 2020
Treatment: Management of acute pain by intravenous injection
Dosage: SOLUTION;INTRAVENOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic